Products

Products

Anhui Liwei Chemical Co., Limited.

Polyvinyl Alcohol (PVA) for Cancer Drug Delivery Carriers

    • Product Name: Polyvinyl Alcohol (PVA) for Cancer Drug Delivery Carriers
    • Factroy Site: Lingwu, Yinchuan, Ningxia, China
    • Price Inquiry: sales2@liwei-chem.com
    • Manufacturer: Anhui Liwei Chemical Co., Limited.
    • CONTACT NOW
    Specifications
    HS Code 875200
    Biocompatibility High, non-toxic to normal cells
    Biodegradability Enzymatically and hydrolytically degradable
    Hydrophilicity Highly hydrophilic due to hydroxyl groups
    Watersolubility Soluble in water, enabling aqueous processing
    Filmformingability Excellent film-forming properties for nanoparticle coating
    Mechanicalstrength Good tensile strength and flexibility
    Chemicalmodificationsites Abundant hydroxyl groups for conjugation of targeting ligands and drugs
    Phresponsiveness Can be engineered for pH-triggered drug release in tumor microenvironments
    Mucoadhesiveproperties Adheres to mucosal surfaces, enhancing localized delivery
    Lowtoxicity Generally recognized as safe with minimal systemic toxicity
    Nonimmunogenicity Low immunogenic response, suitable for repeated administration
    Drugloadingcapacity Capable of encapsulating hydrophilic and hydrophobic drugs via formulation
    Controlledreleaseprofile Supports sustained and controlled drug release kinetics
    Thermalstability Stable at physiological temperatures
    Molecularweightvariability Available in various molecular weights to tailor degradation and release

    As an accredited Polyvinyl Alcohol (PVA) for Cancer Drug Delivery Carriers factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.

    Packing & Storage
    Packing Sterile, sealed glass vial containing 100 g of pharmaceutical-grade Polyvinyl Alcohol (PVA), ensuring purity for cancer drug delivery carrier formulation.
    Container Loading (20′ FCL) 20′ FCL loading of PVA for cancer drug carriers: sealed pharmaceutical-grade drums on pallets, properly secured, labeled, and protected for safe transport.
    Shipping Polyvinyl Alcohol (PVA) for cancer drug delivery carriers ships as a dry, white powder in sealed, moisture-resistant containers. Store in a cool, dry, well-ventilated area away from ignition sources. Protect from humidity and contamination. No special hazard classification; use standard PPE and follow pharmaceutical handling protocols.
    Storage Store Polyvinyl Alcohol (PVA) for cancer drug delivery carriers in a tightly sealed, moisture-proof container, in a cool, dry, well-ventilated area away from direct sunlight, heat sources, and oxidizing agents. Maintain temperatures between 15–25°C. Ensure container remains closed when not in use to prevent humidity absorption and contamination, preserving polymer integrity and performance.
    Shelf Life PVA carriers remain stable for up to 2 years when stored dry, cool, and protected from light.
    Application of Polyvinyl Alcohol (PVA) for Cancer Drug Delivery Carriers
    Production of drug‑eluting embolic beads based on sulphonated polyvinyl alcohol begins with a raw polymer lot that meets a minimum hydrolysis degree of 98.5% and a dynamic viscosity of 45–55 mPa·s in a 4% aqueous solution at 20°C. The feedstock is dissolved under nitrogen blanketing to minimise oxidative chain scission, filtered through a 0.45 µm polypropylene depth filter, and pumped into a coaxial microfluidic droplet generator where the dispersed phase meets a continuous phase of medium‑chain triglyceride containing a non‑ionic surfactant. Spherical droplets are cross‑linked via a two‑stage process: initial ionic gelation with 3% calcium chloride followed by covalent sulphonation using 1,3‑propane sultone at pH 10.2 for 6 h at 50°C to introduce anionic sulphonate groups that will later serve as ion‑exchange sites for cationic chemotherapeutics. Beads are then washed by counter‑current cross‑flow filtration with water for injection until residual sultone is below the limit of detection of < 0.1 ppm when tested by LC‑MS/MS, a step that routinely consumes 8–12 wash volumes in a 500 L‑scale batch. Calibrated sizing through a stack of analytical sieves with mesh openings verified against ISO 3310‑1 yields four clinical fractions: 100–300 µm, 300–500 µm, 500–700 µm, and 700–900 µm. Each sieve cut must exhibit a span factor (d90−d10)/d50 of less than 0.8 to comply with the particle size distribution requirements of ISO 13175:2022 clause 7.3, and any lot with ≥1% of particles falling outside the labelled range is rejected.Drug loading is performed by incubating the pre‑swollen beads in a doxorubicin hydrochloride solution at 25 mg/mL and 37°C for 60–90 min while gently agitating on an orbital shaker at 50 rpm. The maximal loading capacity, documented at 36–45 mg of doxorubicin per millilitre of hydrated bead volume, is governed by the density of accessible sulphonate residues and by the protonation state of the drug’s primary amine; loading efficiency drops below 90% when the external pH exceeds 5.2 because the amine remains largely deprotonated and unavailable for ion exchange. Post‑loading beads are rinsed with 0.9% sodium chloride and resuspended in a non‑ionic contrast medium, typically iohexol 300 mg I/mL, to a concentration of 2–4 mL bead sediment per 20 mL injectable suspension. The suspension must pass a syringe‑push force test through a 2.7 Fr microcatheter with a 0.027‑inch inner lumen: a peak force of < 12 N at a push rate of 1 mL/min is required to avoid catheter blow‑out, measured on a texture analyser equipped with a 50 N load cell following the catheter‑push protocol described in ASTM F2475‑11. Beads that permanently deform under 15% compressive strain and shed fragments larger than 10 µm are flagged for non‑conformity; this specification is verified by a custom‑built radial compression jig that emulates the tortuous pathway of a hepatic artery with 2.5 mm radius bends. Final sterilisation by steam at 121°C for 20 min induces a reversible volume contraction of 12–15%, which must be pre‑compensated in the loading calculation, and the equilibrium water content of the sterilised bead gravimetrically determined after 24 h immersion in phosphate‑buffered saline at pH 7.4 must remain within 92–96 wt%.
    Properties of commercial PVA embolic beads across clinical size fractions – typical ranges
    Size fraction (µm)Doxorubicin loading (mg/mL hydrated beads)Radial compression modulus (kPa) (1)Catheter push force (N) (2)Fines generation < 10 µm (%)
    100–30042–4528–3510–12≤0.2
    300–50038–4218–248–10≤0.1
    500–70030–3612–185–8≤0.05
    (1) Measured with a 2 mm flat probe at 30% strain. (2) 2.7 Fr straight microcatheter, 1 mL/min push rate, 20 mL syringe.Downstream handling note: do not combine sulphonated PVA microspheres with mitoxantrone or other planar aromatic cations before evaluating binding kinetics, as instantaneous complexation can generate a gel‑like shell that blocks catheter lumens. In routine quality audits, the failure mode of “sticky batch” originated from residual calcium ions exceeding 50 ppm in the final product, traced back to insufficient washing after calcium chloride gelation; a revision of the wash protocol to include a 0.1 M EDTA chelation step at 40°C for 30 min eliminated the phenomenon across three subsequent commercial‑scale runs of 120 L bead slurry each.

    What Governs Particle Elastic Modulus During Microcatheter Delivery?

    The elastic modulus of a hydrated embolic particle directly determines its ability to traverse a tortuous catheter trajectory without fragmenting. At the core, the effective cross‑link density achieved during sulphonation, quantified by the number of 1,3‑propane sultone molecules grafted per gram of dry PVA, controls the modulus. An inverse‑phase titration of sulphonate groups with cetylpyridinium chloride according to Ph. Eur. 10.0 method 2.5.8 gives a target range of 0.48–0.62 mmol/g for a 300–500 µm bead that must exhibit a modulus of 18–24 kPa at 30% strain. When the sulphonate density falls below 0.40 mmol/g, the bead collapses into an ellipsoid during passage through a 0.021‑inch guidewire curve and generates micro‑fragments that can non‑target distal embolisation; when it exceeds 0.70 mmol/g, the bead becomes excessively brittle and cracks during syringe‑push acceleration ramps of 1 mL/s. A secondary but operationally critical variable is the equilibration time in phosphate‑buffered saline prior to drug loading: hydration‑induced stress relaxation reaches steady state only after 18–24 h at 37°C, and modulus measurements taken after 3 h of soaking systematically overestimate the in‑situ mechanical compliance by 20–25%, leading to catastrophic under‑dosing of the sieve fraction. On a twin‑screw compounding line that pre‑mixes PVA with calcium carbonate porogen before droplet extrusion, the calendaring gap must be maintained at 0.8–1.0 mm to prevent pre‑gelation shear that produces hard agglomerates visible as high‑modulus outliers in the final bead population; this variable alone accounted for a 4.5% batch rejection rate over a 12‑month production window before the gap was instrumented with a laser micrometer looped into the PLC.

    A 1% w/v aqueous solution of polyvinyl alcohol partially hydrolysed to 87–89% and exhibiting a molecular weight of 13,000–23,000 g/mol acts as the steric colloid stabiliser during single‑emulsion solvent evaporation of poly(lactic‑co‑glycolic acid) nanoparticles encapsulating paclitaxel. In a jacketed glass reactor of 20 L working volume equipped with a high‑shear rotor‑stator disperser, 500 mL of dichloromethane containing 4% w/v PLGA (lactide:glycolide molar ratio 50:50, inherent viscosity 0.32–0.44 dL/g in chloroform at 30°C) and 0.5% w/v paclitaxel is emulsified into 2 L of the PVA aqueous phase at 10,000 rpm for 3 min, generating a crude emulsion with a mean droplet size around 160 nm. Solvent stripping under reduced pressure at 100 mbar and 28°C for 120 min hardens the nanoparticles to a final hydrodynamic diameter of 140–180 nm and a polydispersity index of 0.08–0.12 as measured by dynamic light scattering per ISO 22412:2017. The zeta potential in 1 mM KCl at pH 7.0 falls between −25 mV and −32 mV (electrophoretic mobility evaluated by ISO 13099‑2:2012), indicating an adequate electrostatic barrier against aggregation. Immediately after particle formation, the excess surfactant must be removed to a residual level below 0.15% w/w of nanoparticle mass, because surface‑bound PVA layers thicker than 4 nm—confirmed by X‑ray photoelectron spectroscopy detected oxygen‑carbon ratio exceeding 0.38—promote an immunoglobulin‑rich protein corona when the nanoparticles are incubated in human plasma at 37°C for 1 h, leading to a 4‑fold increase in macrophage uptake in a J774A.1 cell line assay. Cross‑flow filtration through a polyethersulfone cassette with 100 kDa nominal molecular weight cut‑off, operated at a transmembrane pressure of 0.5 bar and a diavolume of 8 exchanges against water for injection, reduces PVA content to 0.06–0.12% with a product loss of less than 2%. In-process validation by a colorimetric method based on boric acid‑iodine complexation at 690 nm serves as the release test; the same method reveals that lyophilisation without a cryoprotectant causes PVA desorption and a concomitant growth in particle size to 220–260 nm upon reconstitution, a shift that contravenes the predefined quality target product profile for a sterile injectable. Storage stability data generated under ICH Q1A (R2) conditions at 5°C and 25°C/60% RH over 12 months demonstrate no statistically significant drift in particle size when mannitol at a 5% w/v ratio is co‑lyophilised with the nanosuspension and the vial headspace oxygen is maintained below 2% by nitrogen overlay.

    When Freeze‑Thaw Physical Crosslinking Replaces Glutaraldehyde for a Tumor Bed Depot

    A sterile 10% w/v aqueous solution of PVA with a hydrolysis degree of ≥99% and a weight‑average molecular weight of 85,000–124,000 g/mol is loaded into a polypropylene mould under ISO class 5 laminar flow and subjected to three freeze‑thaw cycles of −20°C for 8 h followed by room‑temperature thawing for 4 h. The cyclic water crystallisation forces polymer chains into domains of high local concentration where hydrogen‑bonded crystallites form permanent physical junctions, yielding a cryogel with a compressive modulus of 18–32 kPa at 20% strain, a value suitable for conformal filling of a liver resection cavity. Before the first freezing cycle, 50 mg of cisplatin per gram of dry polymer is dissolved directly into the PVA solution; the drug remains homogenously entrapped and its release over 14 days in simulated peritoneal fluid at 37°C follows a biphasic profile with an initial burst of < 18% in the first 6 h and a zero‑order release segment between 24 h and 168 h. The ratio of drug retained within the gel matrix after 14 days exceeds 78% when the freeze‑thaw protocol includes a 2°C/min cooling ramp; rapid quenching at −80°C generates micro‑cracks observed by cryo‑SEM that double the burst release and shorten the zero‑order phase by 40%. Implant sterilisation by ethylene oxide at 55°C and 600 mg/L gas concentration for 3 h reduces molecular weight by 8% but does not alter the cumulative drug release profile beyond the acceptance interval of ±7% at the 72‑h sampling point, while gamma irradiation at 25 kGy causes cross‑linking scission and a 4‑fold increase in extractable oligomers measurable by size‑exclusion chromatography, rendering EtO the only acceptable terminal sterilisation method. Biocompatibility of the finished implant is evaluated under ISO 10993‑5:2009 with L929 fibroblasts and under ISO 10993‑10:2021 for skin sensitisation; the approval dossier also requires a limitation statement that the cryogel must not be implanted in a field receiving concurrent hyperthermic chemotherapy because the pore architecture collapses at temperatures above 50°C, blocking drug release.

    Electrospun nanofibre meshes composed of PVA and methotrexate are fabricated by feeding a solution of 8% w/v fully hydrolysed PVA (98% hydrolysis, Mw 146,000–186,000) and 5% w/w methotrexate relative to polymer into a single‑nozzle electrospinning apparatus under the following fixed parameters: applied voltage 18 kV, needle‑to‑collector distance 14 cm, and feed rate 0.8 mL/h. The resulting non‑woven mat, collected on a rotating stainless‑steel drum at 300 rpm, exhibits a mean fibre diameter of 200 ± 35 nm and an average pore area of 0.45 µm² as quantified by capillary flow porometry. After conditioning at 23°C and 50% relative humidity for 24 h, the mesh is cross‑linked by exposure to glutaraldehyde vapour in a sealed desiccator at 50°C for 4 h, a step that reduces water solubility from total dissolution to a mass loss of < 6% after 72 h in phosphate‑buffered saline at 37°C. The methotrexate release, monitored by USP apparatus V at 50 rpm in 900 mL of phosphate buffer pH 7.4, records a cumulative release of 82% at 24 h with a plateau at 92% after 48 h. Post‑surgical implantation of the mesh onto the peritoneal surface of a porcine model demonstrated a tissue apposition force of > 0.2 N/cm² measured by a peel test at 90°, adequate for adhesion without suture fixation for 72 h. In manufacturing, batch‑to‑batch consistency is maintained by logging ambient humidity: electrospinning at relative humidity above 60% produces localised bead‑on‑string defects in > 25% of the scanned area, whilst humidity below 25% accelerates solvent evaporation to the point where Taylor cone instability causes fibre diameter variability exceeding a CV of 35%, both conditions triggering automatic rejection of the mat.

    Yttrium‑90 Retention in PVA Microsphere Matrices — A Radiochemical Purity Audit

    In the synthesis route for radioembolisation spheres, non‑sulphonated PVA microspheres with a diameter of 20–60 µm are first hydrated in 0.05 M ammonium acetate buffer at pH 5.5 and then mixed with yttrium‑90 chloride solution in a hot‑cell manipulator. The 90Y is incorporated through surface precipitation as the insoluble hydroxide, followed by a sealing coat of 0.5% w/v chitosan chloride that retards radionuclide leakage. Quality control requires measurement of the elutable fraction: 1 mL of the suspension is incubated in 10 mL human serum at 37°C for 72 h under gentle agitation, after which the supernatant must contain < 5% of the original radioactivity as determined by gamma scintillation counting calibrated against a standard of known activity traceable to a national metrology institute. This threshold, tighter than the compendial limit of < 10% in USP <823>, is driven by clinical risk of bone marrow suppression from free 90Y. The particle size distribution is analysed by laser diffraction immediately after labelling because the chitosan coating increases the d50 by 3–5 µm; the final product must comply with a d90/d10 ratio of ≤1.8 to ensure homogenous distribution in the hepatic artery. Terminal sterilisation is not applied because the high‑energy beta emission from 90Y (Emax 2.28 MeV) delivers a self‑sterilising dose exceeding 25 kGy within the first 24 h, validated by bioburden monitoring of three consecutive production campaigns where each pre‑labelled batch contained < 1 CFU/mL and remained sterile after 48 h as per Ph. Eur. 2.6.1. The entire process is designed around an incompatibility window: contact with organic solvents must be avoided because residual dichloromethane or ethanol interferes with the hydroxide precipitation equilibrium, shifting the leachable fraction upward by 2‑ to 3‑fold in an hour‑long contact test.

    Polyvinyl alcohol at a hydrolysis degree of 86–89% and a average degree of polymerisation of 500–600 is dissolved at 40% w/w in a binary solvent system of 70:30 (v/v) ethanol‑water together with 1% w/w 5‑fluorouracil relative to total solution mass, and cast into a silicone mould with 500 µm microneedle cavities under vacuum of −0.08 MPa for 30 min to eliminate air bubbles. After drying at 35°C for 6 h under laminar airflow, the array of 10 × 10 needles with a tip radius below 5 µm is peeled from a backing layer of 100 µm thickness. The insertion capability is tested on a skin‑mimetic substrate of polydimethylsiloxane with an elastic modulus of 2.8 MPa: a minimum force of 0.15 N per needle achieves 100% penetration at a speed of 5 mm/min as recorded by a micromechanical tester. Dissolution kinetics in PBS pH 5.5 to mimic the tumour microenvironment show complete needle dissolution within 12 min and a concomitant release of 95% of the encapsulated 5‑fluorouracil within 20 min. All batches are inspected for methyl methacrylate monomer leaching (injection moulds are not permissible) and for heavy metals — lead and arsenic must each be below 1 ppm, consistent with ICH Q3D parenteral thresholds. An operational note from a production site: conditioning of the casting room at 25% RH led to premature vitrification of the needle surface, reducing drug recovery to 72% because a skin layer formed before complete solvent extraction; installation of a humidity‑controlled glovebox maintaining 50 ± 3% RH returned the recovery to 93–97% over ten successive lots of 500 patches each.

    Free Quote

    Competitive Polyvinyl Alcohol (PVA) for Cancer Drug Delivery Carriers prices that fit your budget—flexible terms and customized quotes for every order.

    For samples, pricing, or more information, please contact us at +8615380400285 or mail to sales2@liwei-chem.com.

    We will respond to you as soon as possible.

    Tel: +8615380400285

    Email: sales2@liwei-chem.com

    Inquiry

    Get Free Quote of Anhui Liwei Chemical Co., Limited.

    Flexible payment, competitive price, premium service - Inquire now!

    Get A Free Quote Now
    Certification & Compliance
    More Introduction

    Polyvinyl Alcohol (PVA) is a synthetic, water-soluble polymer produced through the controlled hydrolysis of polyvinyl acetate. In the context of cancer drug delivery carriers, its utility derives from the ability to precisely tune crystallinity, hydrogel mesh size, and degradation profile via two structural variables: the degree of hydrolysis (specified as the molar percentage of hydrolyzed acetate groups) and the weight-average molecular weight (Mw). Commercially available grades intended for parenteral or implantable pharmaceutical applications conform to monographs in the United States Pharmacopeia (USP 43–NF 38), European Pharmacopoeia (Ph.Eur. 10.0), and Japanese Pharmacopoeia (JP XVIII). The polymer is listed in the FDA Inactive Ingredients Guide for intravenous, intramuscular, and ophthalmic routes. A distinguishing characteristic from other hydrophilic biomaterials such as poly(ethylene glycol) (PEG) or hydroxypropyl methylcellulose (HPMC) is the stereoregularity of the vinyl backbone, which permits physical crosslinking through repeated freeze-thaw cycles without the addition of chemical crosslinkers—an advantage in reducing cytotoxic leachables during carrier fabrication. Typical residual acetyl content ranges from 0.1 mol% for fully hydrolyzed grades to 12.5 mol% for highly water-swellable partially hydrolyzed variants, directly controlling the aqueous solubility over the temperature range of 20–80 °C. Processing into microspheres, electrospun nanofibers, or injectable in situ gelling depots is accomplished using aqueous solutions, eliminating the need for organic solvents that risk denaturing peptide or protein-based antineoplastic payloads.

    What Separates PVA Grades for Chemoembolization Beads from Those Suited for Nanoparticle Lyophilization?

    The selection of a specific PVA grade for a cancer drug delivery system hinges on the interplay between 4% aqueous solution viscosity (measured at 20 °C per USP <911>), molecular weight distribution, and residual acetyl content. For transarterial chemoembolization beads, a high-molecular-weight grade with Mw between 125,000 g/mol and 205,000 g/mol and a degree of hydrolysis exceeding 98.0 mol% is employed. The corresponding dynamic viscosity of a 4% w/v aqueous solution typically falls within 56–72 mPa·s. Such grades exhibit a gel fraction after five freeze-thaw cycles (freezing at -20 °C for 8 h, thawing at 25 °C for 4 h) exceeding 85%, as determined gravimetrically after water extraction at 37 °C. The high crystallinity—reflected in a melting endotherm peak temperature near 228 °C by differential scanning calorimetry—imparts compressive moduli of 40–180 kPa for cryogels at 10% w/v initial polymer concentration, sufficient to withstand arterial shear stresses during catheter delivery. In contrast, for nanoparticle lyophilization and redispersion, a lower molecular weight partially hydrolyzed grade (e.g., Mw between 31,000 g/mol and 50,000 g/mol, hydrolysis 87–89 mol%) is preferred. The viscosity of a 4% solution remains below 6.0 mPa·s, enabling high-shear homogenization at 15,000–24,000 rpm (Ultra-Turrax T25, S25N-25G dispersing tool) without excessive viscous heating. The acetyl groups disrupt intermolecular hydrogen bonding, reducing the glass transition temperature to 45–55 °C and preventing irreversible nanoparticle aggregation during freeze-drying when used as a cryoprotectant at 1–3% w/v.

    Evaluating Sterilization-Induced Structural Alterations in Terminal Processing

    Terminal sterilization of PVA-based cancer drug carriers imposes measurable changes in molecular weight distribution and swelling kinetics, and the selection of the sterilization modality must match the grade’s thermal and radiation sensitivity. Steam sterilization at 121 °C for 20 min in an autoclave without an external pH modifier induces hydrolysis of residual acetyl groups in partially hydrolyzed grades. For a PVA with 11.2 mol% residual acetyl, autoclaving in phosphate-buffered saline at pH 7.4 reduces the acetyl content to 8.9 mol% and lowers the equilibrium swelling ratio (weight change from dry to hydrated state) from 9.3 ± 0.4 to 7.1 ± 0.3 after a single cycle. This shift accelerates the release of hydrophilic cytotoxic agents, shortening the time to 80% cumulative release from 72 h to 48 h in vitro (paddle method, 37 °C, 50 rpm). Gamma irradiation at a dose of 25 kGy (common for pharmaceutical terminal sterilization per ISO 11137-2:2013) generates hydroxyl radicals in the aqueous state, leading to simultaneous chain scission and intermolecular crosslinking. Gel permeation chromatography traces after exposure often exhibit a bimodal molecular weight distribution with a reduced number-average molecular weight (Mn decrease of 18–30% for a starting Mn of 85,000 g/mol) and a high-molecular-weight shoulder corresponding to crosslinked fractions. Dry-state PVA scaffolds irradiated under nitrogen atmosphere exhibit predominantly crosslinking, with gel content increasing to 92% from an initial 78%, whereas hydrated irradiation skews towards chain scission. For doxorubicin-loaded PVA hydrogels fabricated from fully hydrolyzed grades, ethylene oxide sterilization at 55 °C with a gas concentration of 600 mg/L for 6 h followed by aeration at 40 °C for 12 h preserves drug loading efficiency within 5% of the as-prepared value, while autoclaving causes a 23% loss due to thermal degradation of the anthracycline moiety.

    While PEG-based stealth carriers dominate the clinical pipeline for liposomal doxorubicin, PVA offers a differentiated degradation and clearance profile that is advantageous for non-systemic, regionally delivered cancer treatments. PEG is excreted renally, with a molecular weight cutoff for glomerular filtration at approximately 30 kDa. PVA with Mw exceeding 70,000 g/mol is not cleared by the kidneys in its non-degraded state and must be functionalized with acid-labile or enzymatically cleavable crosslinks (e.g., hydrazone bonds, matrix metalloproteinase-sensitive peptide sequences) to enable bioelimination. In the absence of such modifications, incomplete resorption of high-molecular-weight PVA has been documented in subcutaneous implantation models at 12 months, which limits its use in systemic intravenous nanocarriers but proves acceptable for intratumoral depots and surgical site implants where mechanical integrity is required for sustained release exceeding 4 weeks. The polymer does not generate acidic autocatalytic degradation products—a significant departure from poly(lactic-co-glycolic acid) (PLGA) carriers that release lactic and glycolic acids, causing local pH values as low as 3.0–4.0 within microsphere cores and potentially denaturing pH-labile biologics. Instead, PVA hydrogels maintain a bulk pH within 6.8–7.2 throughout the release period when buffered by interstitial fluid, as confirmed by microelectrode measurements in intratumoral dialysis sampling.

    Representative PVA Grades and Critical Specification Ranges for Drug Delivery Carrier Design
    ParameterPartially Hydrolyzed (Low MW)Partially Hydrolyzed (Medium MW)Fully Hydrolyzed (High MW)Reference Standard
    Degree of hydrolysis87.0–89.0 mol%87.0–89.0 mol%≥98.0 mol%Ph.Eur. 2.2.9, USP monograph
    Weight-average molecular weight (Mw)31,000–50,000 g/mol85,000–124,000 g/mol145,000–205,000 g/molGPC, polyethylene oxide equivalent
    Viscosity, 4% aq. at 20°C4.0–6.0 mPa·s23–27 mPa·s56–72 mPa·sUSP <911>, Brookfield LV
    Glass transition temperature (Tg)45–55 °C (dry)58–68 °C (dry)75–85 °C (dry)DSC, 10 °C/min N2 purge
    Typical cancer carrier formatNanoparticle lyoprotectant, injectable dispersionsElectrospun nanofiber mats, filmsFreeze-thaw cryogels, chemoembolization microspheres—
    Equilibrium swelling ratio (PBS, 37°C)6–10 (w/w)4–6 (w/w)2–4 (w/w)Gravimetric after 24 h immersion

    Modulating Tumor Microenvironment-Triggered Release via Dynamic Covalent PVA Networks

    Incorporation of phenylboronic acid-diol dynamic covalent bonds into PVA matrices exploits the elevated reactive oxygen species (ROS) and acidic pH of the tumor milieu to confer site-specific release. PVA possessing 1,2-diol and 1,3-diol sequences along the backbone reacts with benzene-1,4-diboronic acid at pH 8.5 to form boronate ester crosslinks. The resulting hydrogels exhibit a storage modulus (G') at 1 Hz and 1% strain of 3.2 kPa at pH 7.4, which drops to 0.38 kPa upon acidification to pH 6.0—typical of the peritumoral extracellular space—and further decreases to 0.11 kPa in the presence of 1 mM H2O2 due to oxidative cleavage of the boronate linkage. The transition enables a 6.8-fold increase in the diffusive permeability of doxorubicin over 48 h compared to non-responsive PVA-glutaraldehyde gels of equal crosslink density. Processing equipment for such carriers includes a dual-syringe mixing system with a static mixer element (length-to-diameter ratio 10:1) to combine the PVA-boronate precursor in 0.1 M sodium carbonate buffer with the drug payload prior to injection, where gelation occurs within 45–90 s at 37 °C in vivo. Published data for this specific configuration in large animal tumor models remains limited; however, subcutaneous xenograft murine studies report tumor-to-plasma doxorubicin ratios of 12.3 ± 2.1 at 24 h post-injection, compared to 2.7 ± 0.8 for free drug.

    Comparative Performance Matrix: PVA vs. Alternative Carrier Polymers for Intratumoral Delivery
    AttributePVA (Fully Hydrolyzed, High MW)PLGA (50:50, Mw 40 kDa)PEG Diacrylate HydrogelChitosan (DDA 85%)Reference Method
    Biodegradability in tissueNegligible without modification; enzymatic oxidation slowBulk erosion, t1/2 4–8 weeksNon-degradable backbone; cleared renally if below thresholdEnzymatic by lysozyme; t1/2 2–6 weeksWeight loss in PBS/lysozyme, 37°C
    Acidic degradation by-productsNone; pH neutralLactic/glycolic acid; internal pH <4.0None from backboneMild acidification from acetyl releaseMicroelectrode pH mapping
    Hydrogel formation without organic solventYes, aqueous freeze-thaw or boronateNo, requires dichloromethane for microspheresYes, UV photoinitiator needed (Irgacure 2959)Yes, aqueous acidic solutions plus genipin crosslinkerVisual gelation test, DMSO residue by GC
    Radiation sterilization toleranceDose-dependent crosslinking; hydrated: chain scissionSevere Mw loss at 25 kGy (–40%)Susceptible to chain scissionModerate scission; –15% MvGPC post-25 kGy gamma
    Stealth behavior (protein adsorption)Low fouling; contact angle 25–35° for hydrated filmsModerate protein adsorptionExcellent antifouling; contact angle <20°Significant protein binding due to positive chargeQCM-D, BSA adsorption at 1 mg/mL
    Compressive modulus (swollen gel, 10% solid)40–180 kPaNot applicable (solid microspheres)10–60 kPa (MW-dependent)20–80 kPaRheometer, parallel plate, 0.1–10% strain

    Electrospun PVA nanofiber mats loaded with paclitaxel and fabricated on a rotating drum collector (1,200 rpm) have been investigated for post-surgical local recurrence suppression in breast cancer models. A system consisting of medium-MW partially hydrolyzed PVA (Mw 85,000–124,000 g/mol, hydrolysis 87–89 mol%) dissolved with paclitaxel at 12% w/w polymer concentration in ethanol/water (1:1 v/v) is electrospun at an applied voltage of 18 kV (positive polarity), a tip-to-collector distance of 15 cm, and a feed rate of 0.8 mL/h through a 21-gauge blunt needle. The resulting fibers exhibit a mean diameter of 340 ± 50 nm (field-emission SEM, 5 kV), with paclitaxel encapsulated in the amorphous state as confirmed by the absence of characteristic melting endotherms at 213–216 °C in differential scanning calorimetry. Residual ethanol content after vacuum drying at 40 °C for 24 h must remain below 0.5% as determined by headspace gas chromatography per USP <467> Option 1. An important operational boundary during electrospinning is the relative humidity of the processing chamber: at RH values exceeding 55%, water vapor condensation on the whipping jet induces bead formation and fiber merging, reducing the specific surface area from 14.3 m²/g (BET, N2 adsorption) to below 6.5 m²/g. The hygroscopic nature of the partially hydrolyzed grade further necessitates pre-drying of the raw powder at 80 °C under vacuum for 4 h before solution preparation, or acceptable viscosity reproducibility within ±5% cannot be maintained batch-to-batch. PVA nanofiber carriers differ from PLGA electrospun mats in that they rapidly hydrate upon contact with peritoneal fluid, transitioning to a conformal hydrogel within 2 min and releasing 60% of the loaded paclitaxel over 14 days via Fickian diffusion (exponent n = 0.43 in Korsmeyer-Peppas model), whereas PLGA fibers degrade through bulk erosion, generating a lag phase of 7 days before significant release onset. This immediate release profile is exploited when rapid tumor bed coverage is clinically desired, while avoiding the acute inflammatory response sometimes triggered by PLGA degradation products.

    We are a chemical manufacturer focused on quality production and reliable delivery. With in-house manufacturing capabilities and strict quality control, we supply high-quality chemical products that industries worldwide trust for their daily operations.

    Quick Links

    Our Products

    WhatsApp

    Fred Wang

    Copyright ©2026. All Rights Reserved | Anhui Liwei Chemical Co., Limited.